IP Library Granted Patent US 11,389,428
Granted Patent B2
US 11,389,428 · App. 17/002,310 · Granted Jul 19, 2022

Controlled-release melatonin compositions and related methods

Inventors: Syed M. Shah (Boca Raton, FL); Daniel Hassan (Boca Raton, FL)
Assignee: Société des Produits Nestlé S.A.
A61K31/4045A61K9/0053A61K9/2013A61K9/2031A61K9/2054A61K9/2059A61K9/2077A61K9/28
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,389,428
App. No.
17/002,310
Granted
Jul 19, 2022
Kind
B2
Abstract

An oral melatonin pharmaceutical dosage form that contains a sustained release dose of melatonin includes melatonin and an acid dispersed in a hydrogel-forming polymer matrix that combine after ingestion to form an acidic hydrogel containing the melatonin.

Claims (25)

1. A controlled-release melatonin product comprising:

a composition comprising melatonin, citric acid, and hydroxypropyl methylcellulose that, when said composition is ingested, forms an aqueous hydroxypropyl methylcellulose gel matrix having melatonin dissolved therein and an internal pH of 2-4 in said aqueous hydroxypropyl methylcellulose gel matrix, wherein:

said composition provides a first release dose of melatonin for assisting in inducement of sleep and a subsequent sustained release dose of melatonin for assisting in sustaining sleep.

2. The product of claim 1 , wherein said first release dose of melatonin is 50% of the melatonin within 1-3 hours after ingestion by a human and said sustained release dose of melatonin is 50% to 90% of the remaining melatonin within 3-9 hours after ingestion by a human.

3. The product of claim 1 , wherein said composition is in a tablet dosage form, multiparticulate-containing dosage form, or a combination thereof.

4. The product of claim 1 , wherein said composition is effective to release substantially all of the melatonin in said composition into a gastrointestinal tract within ten hours after oral ingestion.

5. The product of claim 1 , wherein said composition further comprises at least one other active ingredient in addition to said melatonin.

6. A sleep-aid product comprising a sleep-aid effective amount of a composition comprising melatonin, hydroxypropyl methylcellulose, and a sufficient amount of citric acid to impart a pH of 2-4 to a gel formed by the hydroxypropyl methylcellulose after oral ingestion by a human subject, wherein said gel formed by the hydroxypropyl methylcellulose solubilizes said melatonin within said gel.

7. The sleep-aid product of claim 6 , wherein:

said composition is effective to release 50% of said melatonin in said composition into said human subject's gastrointestinal tract within 1-3 hours after oral ingestion; and

said composition is effective to release 50% to 90% of the remaining melatonin within 3-9 hours after ingestion.

8. The product of claim 6 , wherein said composition is effective to release approximately 50% of said melatonin in said composition into said human subject's gastrointestinal tract within approximately two hours after oral ingestion.

9. The product of claim 6 , wherein said composition further comprises at least one other active ingredient in addition to said melatonin.

10. The product of claim 6 , wherein said sleep-aid effective amount includes 5 micrograms to 10 milligrams of said melatonin.

11. The product of claim 6 , wherein said composition is in a tablet dosage form, multiparticulate-containing dosage form, or a combination thereof.

12. The product of claim 6 , wherein said composition is effective to release substantially all of the remaining melatonin in said composition into said human subject's gastrointestinal tract within approximately ten hours after oral ingestion.

13. The product of claim 6 , wherein said composition is effective to release substantially all of the remaining melatonin in said composition into said human subject's lower gastrointestinal tract within ten hours after oral ingestion.

14. The product of claim 6 , wherein said citric acid is sufficient to maintain said pH for at least 7 hours.

15. A controlled-release melatonin product comprising:

a compressed tablet comprising melatonin, citric acid, microcrystalline cellulose, and a hydroxypropyl methylcellulose that combine after ingestion to form an acidic hydrogel that dissolves said melatonin and is effective to provide a first release dose of melatonin for assisting in inducement of sleep and a subsequent sustained release dose of melatonin for assisting in sustaining sleep while in a human subject's gastrointestinal tract, the amount of citric acid being sufficient to impart a pH of 2-4 to said hydrogel; wherein:

said first release dose of melatonin is 50% of the melatonin within 1-3 hours after ingestion; and

said sustained release dose of melatonin is 50% to 90% of the remaining melatonin within 3-9 hours after ingestion.

16. The product of claim 15 , wherein said tablet is effective to release substantially all of the remaining melatonin in said tablet into said human subject's gastrointestinal tract within ten hours after oral ingestion.

17. The product of claim 15 , wherein said tablet is effective to release substantially all of the remaining melatonin in said tablet into said human subject's lower gastrointestinal tract over within ten hours after oral ingestion.

18. The product of claim 15 , wherein said tablet further comprises at least one other active ingredient in addition to said melatonin.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 3, 2022
From: PHYSICIAN'S SEAL, LLC
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 059159/0855 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 7, 2020
From: ZX PHARMA, LLC
To: PHYSICIAN'S SEAL, LLC
Reel/Frame 054564/0575 →
Continuity (7)
Continuation 16298552 · Mar 11, 2019
Continuation 15412963 · Jan 23, 2017
Continuation 14942299 · Nov 16, 2015
Division 14186599 · Feb 21, 2014
Continuation 13359638 · Jan 27, 2012
Provisional Application 61437217 · Jan 28, 2011
Related Publication 20200383949A1 · Dec 10, 2020